305 related articles for article (PubMed ID: 26686309)
21. Extended use of bemiparin as thromboprophylaxis during bariatric surgery: results of anti-factor Xa activity measurements.
Muñoz-Atienza V; Gil-Rendo A; Amo-Salas M; Núñez-Guerrero P; Martín-Fernández J
Surg Obes Relat Dis; 2018 Mar; 14(3):354-360. PubMed ID: 29361459
[TBL] [Abstract][Full Text] [Related]
22. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
[TBL] [Abstract][Full Text] [Related]
23. Relation of antifactor-Xa peak levels and venous thromboembolism after trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Martin AG; Lineen EB; Namias N; Schulman CI; Proctor KG
J Trauma Acute Care Surg; 2017 Dec; 83(6):1102-1107. PubMed ID: 29190255
[TBL] [Abstract][Full Text] [Related]
24. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience.
Shapiro NL; Kominiarek MA; Nutescu EA; Chevalier AB; Hibbard JU
Pharmacotherapy; 2011 Jul; 31(7):678-85. PubMed ID: 21923455
[TBL] [Abstract][Full Text] [Related]
25. Fixed or Weight-Tiered Enoxaparin After Thoracic Surgery for Venous Thromboembolism Prevention.
Pannucci CJ; Fleming KI; Bertolaccini C; Moulton L; Stringham J; Barnett S; Lin J; Varghese TK
Ann Thorac Surg; 2020 Jun; 109(6):1713-1721. PubMed ID: 32045583
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients.
Kramme K; Sarraf P; Munene G
J Am Coll Surg; 2020 Mar; 230(3):314-321. PubMed ID: 31843692
[TBL] [Abstract][Full Text] [Related]
27. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
[TBL] [Abstract][Full Text] [Related]
28. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study.
Hamad GG; Choban PS
Obes Surg; 2005; 15(10):1368-74. PubMed ID: 16354513
[TBL] [Abstract][Full Text] [Related]
29. The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients.
Schijns W; Deenen MJ; Aarts EO; Homan J; Janssen IMC; Berends FJ; Kaasjager KAH
Obes Surg; 2018 Jul; 28(7):1997-2005. PubMed ID: 29404935
[TBL] [Abstract][Full Text] [Related]
30. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery.
Simone EP; Madan AK; Tichansky DS; Kuhl DA; Lee MD
Surg Endosc; 2008 Nov; 22(11):2392-5. PubMed ID: 18594915
[TBL] [Abstract][Full Text] [Related]
31. Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial.
Kakkar AK; Agnelli G; Fisher W; George D; Lassen MR; Mismetti P; Mouret P; Murphy J; Lawson F; Turpie AG;
Ann Surg; 2014 Jun; 259(6):1073-9. PubMed ID: 24374549
[TBL] [Abstract][Full Text] [Related]
32. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
33. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Weitz JI; Cao C; Eriksson BI; Fisher W; Kupfer S; Raskob G; Spaeder J; Turpie AG
Thromb Haemost; 2010 Dec; 104(6):1150-7. PubMed ID: 20886185
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery.
Baumgartner JM; McKenzie S; Block S; Costantini TW; Lowy AM
J Surg Res; 2018 Jan; 221():183-189. PubMed ID: 29229126
[TBL] [Abstract][Full Text] [Related]
35. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients.
Costantini TW; Min E; Box K; Tran V; Winfield RD; Fortlage D; Doucet J; Bansal V; Coimbra R
J Trauma Acute Care Surg; 2013 Jan; 74(1):128-33; discussion 134-5. PubMed ID: 23271087
[TBL] [Abstract][Full Text] [Related]
36. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
Marlovits S; Striessnig G; Schuster R; Stocker R; Luxl M; Trattnig S; Vécsei V
Arthroscopy; 2007 Jul; 23(7):696-702. PubMed ID: 17637403
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
[TBL] [Abstract][Full Text] [Related]
38. Enoxaparin dosing after cesarean delivery in morbidly obese women.
Overcash RT; Somers AT; LaCoursiere DY
Obstet Gynecol; 2015 Jun; 125(6):1371-1376. PubMed ID: 26000508
[TBL] [Abstract][Full Text] [Related]
39. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.
Lachish T; Rudensky B; Slotki I; Zevin S
Pharmacotherapy; 2007 Oct; 27(10):1347-52. PubMed ID: 17896889
[TBL] [Abstract][Full Text] [Related]
40. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients.
Rondina MT; Wheeler M; Rodgers GM; Draper L; Pendleton RC
Thromb Res; 2010 Mar; 125(3):220-3. PubMed ID: 19272635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
